Zevra Therapeutics, Inc.
ZVRA
$7.98
-$0.23-2.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 103.96% | -86.01% | -129.13% | -339.38% | -301.09% |
| Total Depreciation and Amortization | 65.24% | 160.18% | 535.09% | 965.13% | 364.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,252.24% | 1,343.47% | 541.72% | 236.58% | 129.43% |
| Change in Net Operating Assets | -628.80% | -956.74% | -212.87% | -136.68% | 35.37% |
| Cash from Operations | 17.56% | -35.19% | -107.74% | -218.57% | -135.46% |
| Capital Expenditure | -27.87% | 62.92% | -- | 72.09% | -114.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -222.72% | -157.67% | -266.54% | 187.72% | -31.93% |
| Cash from Investing | 25.29% | -276.57% | -27.44% | 78.23% | -215.08% |
| Total Debt Issued | -100.00% | 95.21% | 37.51% | 59.03% | 538.18% |
| Total Debt Repaid | 99.22% | -790.91% | -138.29% | -246.78% | -230.58% |
| Issuance of Common Stock | 777.42% | 802.00% | 963.54% | 22,091.74% | 2,766.79% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -3,175.00% | -3,175.00% |
| Cash from Financing | 43.38% | 146.77% | 188.46% | 272.00% | 1,479.80% |
| Foreign Exchange rate Adjustments | -10.56% | 292.42% | 931.82% | 213.79% | 52,000.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.38% | -306.48% | 58.67% | 140.20% | -154.52% |